Uvax Bio
Blood & Organ Banks · Delaware, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Biddle Ave Ste 202, Newark, Delaware...Website
www.uvaxbio.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
2
3
3
2
About Uvax Bio
Uvax Bio is a biotech pharmaceutical company focused on developing safe and effective vaccines using their proprietary 1c-SA NP Vaccine platform. Their technology employs stable, multi-layered protein nanoparticles to deliver designed antigens that elicit protective immune responses against infectious diseases. The company aims to become a global leader in the vaccine industry by addressing unmet public health needs through innovative vaccine solutions. Uvax Bio is currently preparing for Phase 1 trials of their HIV-1 vaccine candidates and has received sponsorship from the National Institutes of Health.Explore more
Uvax Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Uvax Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Uvax Bio has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Uvax Bio is spiking on competitors!
Earning: See what the market has to say on Uvax Bio recently announced quarterly report
Click to see if Uvax Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Uvax Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Uvax Bio
Product Launch: Get notified when Uvax Bio launches new products
Uvax Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Uvax Bio
Compare insights from companies similar to Uvax Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Uvax Bio is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Uvax Bio is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Uvax Bio.
Uvax Bio Tech Stack
A closer look at the technologies used by Uvax Bio
See more technologies
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
New Hire
Executive Move
Uvax Bio News & Media
Uvax Bio Announces Interim Results from a Phase 1 Clinical Trial Evaluating its HIV-1 Vaccine
NEWARK, Del.--(BUSINESS WIRE)--Uvax Bio, LLC Phase 1 HIV-1 Vaccine Interim Analysis #1Uvax Bio Announces Dosing of First Participant in Phase 1 Clinical Trial Evaluating Two Vaccines to Prevent HIV-1 Infection
NEWARK, Del.--(BUSINESS WIRE)--Uvax Bio, LLC, (“Uvax” or “the Company”) a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP® protein-based vaccines, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating the Company’s HIV-1 vaccine candidates, UVAX-1107 and UVAX-1197, in healthy volunteers in Australia. “With an estimated 1.3 million people worldwide becoming infected with HIV annUvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia
NEWARK, Del.--(BUSINESS WIRE)--Uvax Bio receives approval to start a Phase 1 clinical study for its novel HIV-1 protein-based vaccine in Australia.Uvax Bio to give a Preclinical Development Update on its HIV-1 Vaccine at the World ...
Uvax Bio, LLC, a privately held, preclinical-stage vaccine development company, today announced that Dr. Jiang Zhu, Associate Professor of Integrative
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Uvax Bio
Sign Up For FreeTo access detailed company insights
Uvax Bio is a biotech pharmaceutical company focused on developing safe and effective vaccines using their proprietary 1c-SA NP Vaccine platform. Their technology employs stable, multi-layered protein nanoparticles to deliver designed antigens that elicit protective immune responses against infectious diseases. The company aims to become a global l... Read More
